Category: esters-buliding-blocks

On July 8, 2010, Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang published an article.COA of Formula: C4H8ClNOS The title of the article was Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification. And the article contained the following:

Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepared as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by preparation of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library. The initial hit compound I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line. On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells. The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes. The experimental process involved the reaction of 3-Aminodihydrothiophen-2(3H)-one hydrochloride(cas: 6038-19-3).COA of Formula: C4H8ClNOS

The Article related to furanopyrimidine combinatorial library preparation aurora egfr kinase inhibitor, structure furanopyrimidine activity aurora egfr kinase inhibitor, optimization furanopyrimidine aurora egfr kinase inhibitor activity, mol crystal structure furanopyrimidine bound aurora egfr kinase and other aspects.COA of Formula: C4H8ClNOS

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 9, 2014, Falkowski, Joseph M.; Sawano, Takahiro; Zhang, Teng; Tsun, Galen; Chen, Yuan; Lockard, Jenny V.; Lin, Wenbin published an article.Electric Literature of 3976-69-0 The title of the article was Privileged Phosphine-Based Metal-Organic Frameworks for Broad-Scope Asymmetric Catalysis. And the article contained the following:

A robust and porous Zr metal-organic framework (MOF) based on a BINAP-derived dicarboxylate linker, BINAP-MOF, was synthesized and post-synthetically metalated with Ru and Rh complexes to afford highly enantioselective catalysts for important organic transformations. The Rh-functionalized MOF is not only highly enantioselective (up to >99% ee) but also 3 times as active as the homogeneous control. XAFS studies revealed that the Ru-functionalized MOF contains Ru-BINAP precatalysts with the same coordination environment as the homogeneous Ru complex. The post-synthetically metalated BINAP-MOFs provide a versatile family of single-site solid catalysts for catalyzing a broad scope of asym. organic transformations, including addition of aryl and alkyl groups to α,β-unsaturated ketones and hydrogenation of substituted alkene and carbonyl compounds The experimental process involved the reaction of (R)-Methyl 3-hydroxybutanoate(cas: 3976-69-0).Electric Literature of 3976-69-0

The Article related to preparation ruthenium rhodium zirconium carboxyphenylethynyl binap hydroxo oxo framework, hydrogenation enantioselective catalyst ruthenium rhodium zirconium binap derivative framework, alkylation enantioselective catalyst ruthenium rhodium zirconium binap derivative framework and other aspects.Electric Literature of 3976-69-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 29, 2007, Hashimoto, Kazuki; Nakamura, Tomoaki; Nakamura, Kei; Kurimoto, Ayumu; Isobe, Yoshiaki published a patent.Quality Control of Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of novel adenine compounds having immunomodulating activity. And the patent contained the following:

Novel N-benzyl- and 9-(3-pyridyl)-7,8-dihydro-8-oxoadenine derivatives represented by the formula (I) [A1, A2 = each (un)substituted aromatic carbocycle or aromatic heterocycle; L4 = independently a single bond or linear or branched alkylene; X = O, S, SO, SO2, NH, or alkyl-N; L1, L2, L3 = single bond, alkylene, alkenylene, or alkynylene wherein any methylene group is optionally replaced with O, S, SO, SO2, CO, or each N-(un)substituted alkyl-(un)substituted NHCO, CONH, NHSO2, SO2NH, NHCO2, O2CNH, NHCONH, NHC(:NH)NH, or C(:NH)NH; R1 = halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl; R2 = H or (un)substituted alkyl; R3 = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, saturated heterocyclyl, aryl, or heteroaryl; any methylene, methine, or imino group in L2 or L3 is bonded to R3 on the N atom adjacent to L2 an dL3 to form 4- to 7-membered N-containing heterocyclic ring] or pharmaceutically acceptable salts thereof were prepared The compounds have activity of activating Toll-like receptor (TLR7) and useful as immunomodulators for treating and/or preventing allergies, viral diseases, and cancers, in particular asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV), human papillomavirus (HPV), bacterial infection, or dermatitis (no data). Thus, mesylation of 2-butoxy-9-[6-(4-hydroxybutoxy)pyridin-3-yl]-8-methoxyadenine by methanesulfonyl chloride in the presence of 4-dimethylaminopyridine and Et3N in THF at room temperature for 30 min followed by condensation with 2-(aminomethyl)phenylacetic acid Me ester in the presence of NaI and K2CO3 in DMF at 60° for 48 h gave 2-butoxy-8-methoxy-9-[6-[4-(3-methoxycarbonylmethylbenzyl)aminobutoxy]pyridin-3-ylmethyl]adenine which was stirred with a mixture of concentrated H2SO4 and MeOH and neutralized with 28% aqueous NH3 solution to give 2-butoxy-7,8-dihydro-9-(6-[4-(3-methoxycarbonylmethylbenzyl)aminobutoxy]pyridin-3-ylmethyl)-8-oxoadenine. II activated human TLR-7 in HEK293 cells with EC50 of 9.1 nM in a human TLR-7 reporter assay. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Quality Control of Methyl 2-(3-formylphenyl)acetate

The Article related to dihydrooxoadenine preparation immunomodulator, pyridinylmethyldihydrooxoadenine benzyldihydrooxoadenine preparation immunomodulator, toll like receptor tlr7 activator dihydrooxoadenine preparation, allergy viral disease cancer treatment prevention dihydrooxoadenine preparation and other aspects.Quality Control of Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 23, 2009, Kurimoto, Ayumu; Katoda, Wataru; Hashimoto, Kazuki; Takahashi, Kazuhiko published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of adenine compound. And the patent contained the following:

The title compounds I [A1 = (CH2)m; A2 = (CH2)n; R1 = alkyl; R2, R3 = H, alkyl; or NR2R3 = pyrrolidine, morpholine, thiomorpholine, etc.; R4 = alkyl; m, n = integer from 2 to 5] are prepared by debenzylation of II [p = 1 or 2; R = H, halo, alkyl, etc.; A1, A2, R1 – R3, m, n = as defined above], followed by reaction with alkyl (3-formylphenyl)acetate in the presence of a boron-containing reducing agent. I are useful as pharmaceuticals (no data). Thus, debenzylation of 6-(benzylamino)-2-butoxy-9-(3-[(3-morpholin-4-ylpropyl)amino]propyl)-7,9-dihydro-8H-purin-8-one, followed by reaction with Me (3-formylphenyl)acetate in the presence of sodium triacetoxyborohydride, gave Me (3-([[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl)phenyl)acetate. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Category: esters-buliding-blocks

The Article related to benzylaminobutoxymorpholinylpropylaminopropyldihydropurinone debenzylation, aminobutoxyoxodihydropurinylpropylmorpholinylpropylaminomethylphenylacetate preparation, aminobutoxymorpholinylpropylaminopropyldihydropurinone reaction formylphenylacetate sodium triacetoxyborohydride and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 20, 2022, Nandi, Shantanu; Mondal, Shuvam; Jana, Ranjan published an article.Application In Synthesis of Phenyl Salicylate The title of the article was Chemo- and regioselective benzylic C(sp3)-H oxidation bridging the gap between hetero- and homogeneous copper catalysis. And the article contained the following:

An expedient synthesis of privileged seven-membered lactones, dibenzo[c,e]oxepin-5(7H)-one through a highly chemoselective benzylic C(sp3)-H activation was disclosed. Remarkably, the formation of widely explored six-membered lactone via C(sp2)-H activation was suppressed under the present conditions. The reaction proceeded smoothly on use of inexpensive metallic copper catalyst and di-tert-Bu peroxide (DTBP). Owing to the hazards of stoichiometric DTBP, further, a sustainable metallic copper/rose bengal dual catalytic system coupled with mol. oxygen replacing DTBP was developed. A 1,5-aryl migration through Smiles rearrangement was realized from the corresponding diaryl ether substrates instead of expected eight-membered lactones. The present methodol. was scalable, applied to the total synthesis of cytotoxic and neuroprotective natural product alterlactone. The catalyst was recyclable and the reaction could be performed in a copper bottle without any added catalyst. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Application In Synthesis of Phenyl Salicylate

The Article related to orthotolylbenzoic acid copper catalyst intramol benzylic oxidation cyclization, photosensitizer orthotolylbenzoic acid copper catalyst intramol benzylic oxidation cyclization, dibenzooxepinone chemoselective regioselective preparation, catalysis, chemistry, organic chemistry and other aspects.Application In Synthesis of Phenyl Salicylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 15, 2021, Meninno, Sara; Villano, Rosaria; Lattanzi, Alessandra published an article.Name: Methyl 2-cyclopentanonecarboxylate The title of the article was Magnesium Monoperphthalate (MMPP): a Convenient Oxidant for the Direct Rubottom Oxidation of Malonates, β-Keto Esters, and Amides. And the article contained the following:

A mild and convenient protocol for the α-hydroxylation of α-substituted malonates, β-ketoesters, and β-ketoamides is disclosed. Cheap and stable magnesium monoperphthalate (MMPP) was effective for a first direct α-hydroxylation protocol of the Rubottom oxidation, providing tartronic esters, cyclic α-hydroxy β-ketoesters and amides in good to high yields, when working at room temperature and in ethanol as the solvent. The protocol has been successfully scaled up to gram quantity. The experimental process involved the reaction of Methyl 2-cyclopentanonecarboxylate(cas: 10472-24-9).Name: Methyl 2-cyclopentanonecarboxylate

The Article related to malonate magnesium monoperphthalate regioselective rubottom hydroxylation, ketoester magnesium monoperphthalate regioselective rubottom hydroxylation, ketoamide magnesium monoperphthalate regioselective rubottom hydroxylation, hydroxy malonate ketoester ketoamide preparation and other aspects.Name: Methyl 2-cyclopentanonecarboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 27, 2020, Crew, Andrew P.; Dong, Hanqing; Berlin, Michael; Sparks, Steven M. published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of proteolysis targeting chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting α-synuclein protein for treating neurodegenerative diseases. And the patent contained the following:

The present disclosure relates to bifunctional compounds, which find utility as modulators of α-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, inhibitors of apoptosis proteins or mouse double-minute homolog 2 ligand which binds to the resp. E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. A bifunctional compounds I [ULM-L-PTM; wherein the ULM = a small mol. E3 ubiquitin ligase binding moiety; the PTM = a small mol. comprising a α-synuclein protein targeting moiety; and the L = a bond or a chem. linking moiety connecting the ULM and the PTM] or pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs or prodrugs thereof, were disclosed. E.g., a multi-step synthesis of II, starting from 2-(2-benzyloxyethoxy)ethanol and tert-Bu 2-bromoacetate, was described. Targeted degradation of sarkosyl insoluble (SI) α-synuclein via exemplary bifunctional compounds I was assessed by MJFF-14-6-4-2 conformation specific ELISA following treatment of PFF-induced A53T α-synuclein overexpressing HEK293 cells with 1μM exemplary compound compared to DMSO vehicle control (data given for representative compounds I). Diseases or disorders that result from aggregation or accumulation of the target protein are α-synucleinopathies or neurodegenerative diseases associated with α-synuclein accumulation and aggregation, such as e.g., Parkinson disease, Alzheimer’s disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson’s disease. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Category: esters-buliding-blocks

The Article related to proteolysis targeting chimeric protac bifunctional compound preparation protein degradation, sarkosyl insoluble alpha synuclein targeted degradation bifunctional compound preparation, alpha synucleinopathy neurodegenerative disease treatment bifunctional compound preparation and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Teixeira, Priscila Camillo; Ducret, Axel; Langen, Hanno; Nogoceke, Everson; Santos, Ronaldo Honorato Barros; Nunes, Joao Paulo Silva; Benvenuti, Luiz; Levy, Debora; Bydlowski, Sergio Paulo; Bocchi, Edimar Alcides; Takara, Andreia Kuramoto; Fiorelli, Alfredo Inacio; Stolf, Noedir Antonio; Pomeranzeff, Pablo; Chevillard, Christophe; Kalil, Jorge; Cunha-Neto, Edecio published an article in 2021, the title of the article was Impairment of multiple mitochondrial energy metabolism pathways in the heart of chagas disease cardiomyopathy patients.Category: esters-buliding-blocks And the article contains the following content:

Chagas disease cardiomyopathy (CCC) is an inflammatory dilated cardiomyopathy occurring in 30% of the 6 million infected with the protozoan Trypanosoma cruzi in Latin America. Survival is significantly lower in CCC than ischemic (IC) and idiopathic dilated cardiomyopathy (DCM). Previous studies disclosed a selective decrease in mitochondrial ATP synthase alpha expression and creatine kinase activity in CCC myocardium as compared to IDC and IC, as well as decreased in vivo myocardial ATP production Aiming to identify addnl. constraints in energy metabolism specific to CCC, we performed a proteomic study in myocardial tissue samples from CCC, IC and DCM obtained at transplantation, in comparison with control myocardial tissue samples from organ donors. Left ventricle free wall myocardial samples were subject to two-dimensional electrophoresis with fluorescent labeling (2D-DIGE) and protein identification by mass spectrometry. We found altered expression of proteins related to mitochondrial energy metabolism, cardiac remodeling, and oxidative stress in the 3 patient groups. Pathways anal. of proteins differentially expressed in CCC disclosed mitochondrial dysfunction, fatty acid metabolism and transmembrane potential of mitochondria. CCC patients’ myocardium displayed reduced expression of 22 mitochondrial proteins belonging to energy metabolism pathways, as compared to 17 in DCM and 3 in IC. Significantly, 6 beta-oxidation enzymes were reduced in CCC, while only 2 of them were down-regulated in DCM and 1 in IC. We also observed that the cytokine IFN-gamma, previously described with increased levels in CCC, reduces mitochondrial membrane potential in cardiomyocytes. Results suggest a major reduction of mitochondrial energy metabolism and mitochondrial dysfunction in CCC myocardium which may be in part linked to IFN-gamma. This may partially explain the worse prognosis of CCC as compared to DCM or IC. The experimental process involved the reaction of Oxybis(ethane-2,1-diyl) bis(2-methylacrylate)(cas: 2358-84-1).Category: esters-buliding-blocks

The Article related to mitochondrial energy metabolism pathway chagas disease cardiomyopathy human, chronic chagas disease cardiomyopathy, energy metabolism, idiopathic dilated cardiomyopathy, interferon-gamma, ischemic cardiomyopathy, mitochondria, proteomics, two-dimensional electrophoresis with fluorescent labeling and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 23, 1999, Buchanan, John; Bohacek, Regine; Vu, Chi B.; Luke, George P. published a patent.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of heterocyclyl phosphotyrosine derivatives as SH2-mediated signal transduction inhibitors. And the patent contained the following:

Heterocyclic phosphotyrosine derivatives were prepared for inhibiting intracellular signal transduction, especially intracellular signal transduction mediated by a PDGF receptor protein, EGF receptor protein, HER2/Neu receptor protein, fibroblast growth factor receptor protein, focal adhesion kinase protein, p130 protein, or p68 protein. For example, BOC-Tyr(PO3Bn2)-OH (BOC = tert-butoxycarbonyl; Bn = benzyl) and the thiazolylamine salt (I)·TFA (four step preparation given) were coupled, the phosphate deprotected, the amine acylated, and the carboxylic acid deprotected to form the title compound (II). In an assay for binding affinities to Src SH2, thirteen compounds of the invention were determined to have IC50 values of < 50μM. In an assay for binding affinities to Zap-70 SH2, fourteen compounds of the invention exhibited IC50 values of < 50μM. This invention also relates to pharmaceutical compositions containing the compounds and prophylactic and therapeutic methods involving pharmaceutical and veterinary administration of the compounds for proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, cardiovascular disease, or immunosuppression. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to peptide heterocyclyl phosphotyrosine preparation signal transduction inhibitor, antitumor heterocyclyl phosphotyrosine preparation antiosteoporotic antiinflammatory antiallergenic immunosuppressant, tyrosine phospho heterocyclyl preparation proliferative disease cardiovascular disease treatment and other aspects.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 17, 2021, Ofman, Tim P.; Kuellmer, Florian; van der Marel, Gijsbert A.; Codee, Jeroen D. C.; Overkleeft, Herman S. published an article.Related Products of 2873-29-2 The title of the article was An Orthogonally Protected Cyclitol for the Construction of Nigerose- and Dextran-Mimetic Cyclophellitols. And the article contained the following:

Cyclophellitols are potent inhibitors of exo- and endoglycosidases. Efficient synthetic methodologies are needed to fully capitalize on this intriguing class of mechanism-based enzyme de-activators. We report the synthesis of an orthogonally protected cyclitol from D-glucal (19% yield over 12 steps) and its use in the synthesis of α-(1,3)-linked di- and trisaccharide dextran mimetics. These new glycomimetics may find use as Dextranase inhibitors, and the developed chemistries in widening the palette of glyco-processing enzyme-targeting glycomimetics. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Related Products of 2873-29-2

The Article related to epoxidation aziridination trisaccharide dextran mimetic cyclitol nigerose cyclophellitol, oligosaccharide trisaccharide dextran cyclophellitol preparation endoglycosidase inhibitor aziridine, trisaccharide dextran cyclophellitol endoglycosidase glycomimetic dextranase inhibitor glucal cyclitol and other aspects.Related Products of 2873-29-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics